Literature DB >> 7031274

Monoclonal antibody covalently coupled to liposomes: specific targeting to cells.

J Barbet, P Machy, L D Leserman.   

Abstract

We have evaluated optimal conditions for coupling monoclonal antibody to small unilamellar liposomes. Coupling of an IgG2 alpha monoclonal anti-beta 2-microglobulin antibody, which reacts with human cells, was examined in detail. Liposomes were composed of dipalmitoyl lecithin and cholesterol, and variable quantities of phosphatidylethanolamine substituted with the heterobifunctional cross-linking reagent N-hydroxysuccinimidyl 3-(2-pyridyldithio) propionate (SPDP). They were reacted with antibody derivatized with the same reagent at a 5- to 20-fold molar excess, and activated by mild reduction. This degree of SPDP modification had no effect on the capacity of the antibody to bind to its target antigen. More than 40% of antibody could be reproducibly bound to liposomes, resulting in the coupling of from 1 to 10 antibody molecules per liposome (mean diameter:580 A). The coupling reaction did not lead to loss of carboxyfluorescein encapsulated within liposomes. At least 80% of liposomes carried nondenatured antibody, as confirmed by precipitation of liposomes and encapsulated carboxyfluorescein by Staphylococcus aureus, strain Cowan I. The liposome-coupled antibody retained its immunological specificity: only cells expressing human beta 2-microglobulin bound liposomes in vitro, and the binding was inhibited by the free antibody in solution. Results with antibodies of different antigens specificity confirm that the technique can be generally applied.

Entities:  

Mesh:

Substances:

Year:  1981        PMID: 7031274     DOI: 10.1002/jsscb.1981.380160305

Source DB:  PubMed          Journal:  J Supramol Struct Cell Biochem        ISSN: 0275-3723


  25 in total

1.  Design of liposome to improve encapsulation efficiency of gelonin and its effect on immunoreactivity and ribosome inactivating property.

Authors:  A Alam; S R Bhuri; A K Mavila; V Singh
Journal:  Mol Cell Biochem       Date:  1992-06-26       Impact factor: 3.396

2.  Improvement of amphotericin B activity during experimental cryptococcosis by incorporation into specific immunoliposomes.

Authors:  F Dromer; J Barbet; J Bolard; J Charreire; P Yeni
Journal:  Antimicrob Agents Chemother       Date:  1990-11       Impact factor: 5.191

3.  Echogenic liposome compositions for increased retention of ultrasound reflectivity at physiologic temperature.

Authors:  Kyle D Buchanan; Shaoling Huang; Hyunggun Kim; Robert C Macdonald; David D McPherson
Journal:  J Pharm Sci       Date:  2008-06       Impact factor: 3.534

4.  Gene transfer from targeted liposomes to specific lymphoid cells by electroporation.

Authors:  P Machy; F Lewis; L McMillan; Z L Jonak
Journal:  Proc Natl Acad Sci U S A       Date:  1988-11       Impact factor: 11.205

5.  Recognition of liposome-bound antigens by antipeptide antibody.

Authors:  Y Sohma; R Fujita; S Katoh; E Sada
Journal:  Appl Biochem Biotechnol       Date:  1993-03       Impact factor: 2.926

Review 6.  Microinjection of somatic cells with micropipettes: comparison with other transfer techniques.

Authors:  J E Celis
Journal:  Biochem J       Date:  1984-10-15       Impact factor: 3.857

Review 7.  Immunoglobulins as targeting agents for liposome encapsulated drugs.

Authors:  P A Toonen; D J Crommelin
Journal:  Pharm Weekbl Sci       Date:  1983-12-16

8.  Differential endocytosis of T and B lymphocyte surface molecules evaluated with antibody-bearing fluorescent liposomes containing methotrexate.

Authors:  P Machy; J Barbet; L D Leserman
Journal:  Proc Natl Acad Sci U S A       Date:  1982-07       Impact factor: 11.205

9.  Use of monoclonal antibodies and liposomes to improve drug delivery. Present status and future implications.

Authors:  G Gregoriadis
Journal:  Drugs       Date:  1982-10       Impact factor: 9.546

Review 10.  Immunoconjugates and long circulating systems: origins, current state of the art and future directions.

Authors:  Alexander Koshkaryev; Rupa Sawant; Madhura Deshpande; Vladimir Torchilin
Journal:  Adv Drug Deliv Rev       Date:  2012-09-03       Impact factor: 15.470

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.